JP2017534591A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534591A5
JP2017534591A5 JP2017516735A JP2017516735A JP2017534591A5 JP 2017534591 A5 JP2017534591 A5 JP 2017534591A5 JP 2017516735 A JP2017516735 A JP 2017516735A JP 2017516735 A JP2017516735 A JP 2017516735A JP 2017534591 A5 JP2017534591 A5 JP 2017534591A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
aryl
heteroaryl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017516735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534591A (ja
JP6770511B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/052611 external-priority patent/WO2016053855A1/en
Publication of JP2017534591A publication Critical patent/JP2017534591A/ja
Publication of JP2017534591A5 publication Critical patent/JP2017534591A5/ja
Application granted granted Critical
Publication of JP6770511B2 publication Critical patent/JP6770511B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017516735A 2014-09-29 2015-09-28 心肺障害の処置のためのスフィンゴシン−1−リン酸受容体モジュレーター Expired - Fee Related JP6770511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462056946P 2014-09-29 2014-09-29
US62/056,946 2014-09-29
PCT/US2015/052611 WO2016053855A1 (en) 2014-09-29 2015-09-28 Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders

Publications (3)

Publication Number Publication Date
JP2017534591A JP2017534591A (ja) 2017-11-24
JP2017534591A5 true JP2017534591A5 (enExample) 2018-10-25
JP6770511B2 JP6770511B2 (ja) 2020-10-14

Family

ID=55631308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516735A Expired - Fee Related JP6770511B2 (ja) 2014-09-29 2015-09-28 心肺障害の処置のためのスフィンゴシン−1−リン酸受容体モジュレーター

Country Status (13)

Country Link
US (2) US10323029B2 (enExample)
EP (1) EP3209732B1 (enExample)
JP (1) JP6770511B2 (enExample)
KR (1) KR102307037B1 (enExample)
CN (1) CN107001806B (enExample)
AU (1) AU2015324163B2 (enExample)
CA (1) CA2962922C (enExample)
EA (1) EA031503B1 (enExample)
ES (1) ES2895174T3 (enExample)
IL (1) IL251387B (enExample)
SG (1) SG11201702483QA (enExample)
WO (1) WO2016053855A1 (enExample)
ZA (1) ZA201702403B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895174T3 (es) 2014-09-29 2022-02-17 Scripps Research Inst Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares
EP3419973B1 (en) 2016-02-24 2020-04-08 Acesion Pharma ApS Novel potassium channel inhibitors
US11049009B2 (en) * 2017-06-12 2021-06-29 Western Digital Technologies, Inc. Identifying memory block write endurance using machine learning
EP3687530A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
CN112469697B (zh) * 2018-07-11 2025-02-14 鲁贝多生命科学公司 抗衰老组合物及其用途
KR102218280B1 (ko) * 2019-01-30 2021-02-22 주식회사 엑세쏘바이오파마 P1p 유도체의 패혈증 치료제 용도
BR112021022067A2 (pt) * 2019-05-03 2022-05-17 Praxis Prec Medicines Inc Inibidores de kcnt1 e métodos de uso
CN113200971B (zh) * 2021-05-14 2022-06-28 济南大学 一类具有芳香基哌嗪结构的吲哚恶二唑衍生物的合成和应用
KR102733257B1 (ko) * 2021-05-17 2024-11-26 에이치케이이노엔 주식회사 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
TW202543610A (zh) 2024-02-19 2025-11-16 日商小野藥品工業股份有限公司 具有s1p受體拮抗活性的雜環衍生物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2085736A (en) * 1933-12-06 1937-07-06 Du Pont Compounds of the triphenylmethane series
US3217012A (en) * 1960-10-26 1965-11-09 Purdue Research Foundation Substituted pyridines, process for and new compositions
US3916000A (en) * 1971-07-21 1975-10-28 Commw Scient Ind Res Org Alkylation process
EP0355864A3 (en) * 1984-03-15 1991-09-18 Wako Pure Chemical Industries, Ltd. Method of quantitatively measuring an oxidative substance by using triphenyl methane type leuco compounds as coloring matter
US6028103A (en) * 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
US20020156301A1 (en) * 1997-06-17 2002-10-24 Sumitomo Chemical Co., Ltd. Triphenylmethane derivatives and use thereof
AU2003202994B2 (en) * 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
ATE482950T1 (de) * 2003-08-27 2010-10-15 Zentiva Ks Verfahren zur entfernung der triphenylmethanschutzgruppe
CN101528699A (zh) * 2005-11-23 2009-09-09 布里斯托尔—迈尔斯斯奎布公司 杂环胆固醇酯转运蛋白抑制剂
US7888376B2 (en) * 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7947712B2 (en) * 2006-08-23 2011-05-24 Wyeth Llc 8-hydroxyquinoline compounds and methods thereof
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
CN102036981B (zh) * 2008-03-18 2015-04-08 默沙东公司 取代的4-羟基嘧啶-5-甲酰胺
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010014948A1 (en) * 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
WO2012074719A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
BR112013013639A2 (pt) 2010-12-03 2016-09-06 Allergan Inc derivados de azetidina como moduladores do receptor de esfingosina-1-fosfato (s1p)
KR20130123419A (ko) * 2010-12-03 2013-11-12 알러간, 인코포레이티드 스핑고신-1-포스페이트 (s1p) 수용체 조절제로서의 옥사디아졸 유도체
EP2723717A2 (en) * 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
DE202013011832U1 (de) * 2012-04-11 2014-07-25 Fluoron Gmbh Färbemittel
US9410058B2 (en) 2014-04-10 2016-08-09 United States Gypsum Company Compositions and methods for water-resistant gypsum fiber products
ES2895174T3 (es) 2014-09-29 2022-02-17 Scripps Research Inst Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares

Similar Documents

Publication Publication Date Title
JP2017534591A5 (enExample)
TWI400234B (zh) 作為組織胺h4受體調節劑之苯并咪唑-2-基嘧啶類及吡類
JP2020531422A5 (enExample)
JP2013523802A5 (enExample)
JP2018534301A5 (enExample)
JP2012507522A5 (enExample)
CN111741769A (zh) 一种多功能化合物、其制备方法及其在医药上的应用
JP2016515096A5 (enExample)
JPWO2022016070A5 (enExample)
JP2015532287A5 (enExample)
JP2020510015A5 (enExample)
JP2019524883A5 (enExample)
JP2016516699A5 (enExample)
JP2018534348A5 (enExample)
JP2016530259A5 (enExample)
JP2011523412A5 (enExample)
JP2016500111A5 (enExample)
JP2016529306A5 (enExample)
JP7644823B2 (ja) ピリドン多環縮合環系誘導体及びその使用
JP2016511753A5 (enExample)
JP2017506666A5 (enExample)
JP2014097964A5 (enExample)
JP2018528182A (ja) 6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジオール及び6−(アリールまたはヘテロアリール)−1,3,5−トリアジン−2,4−ジアミンを調製する方法
JP2017537886A5 (enExample)
JP2012526769A5 (enExample)